Literature DB >> 19136509

Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.

J-S Ren1, F Kamangar, Y-L Qiao, P R Taylor, H Liang, S M Dawsey, B Liu, J-H Fan, C C Abnet.   

Abstract

OBJECTIVE: Low serum pepsinogen I (PGI) and low pepsinogen I/pepsinogen II ratio (PGI/II ratio) are markers of gastric fundic atrophy. We aimed to prospectively test the association between serum PGI/II ratio and risks of gastric non-cardia adenocarcinoma, gastric cardia adenocarcinoma, and oesophageal squamous cell carcinoma (OSCC).
DESIGN: Case-cohort study nested in a prospective cohort with over 15 years of follow-up.
SETTING: Rural region of the People's Republic of China.
SUBJECTS: Men and women aged 40-69 years at study baseline. MAIN OUTCOME MEASURES: Adjusted hazard ratios and 95% confidence intervals for the association between serum PGI/II ratio and cancer risk.
RESULTS: Compared to subjects with PGI/II ratio of >4, those with <or=4 had hazard ratios (HRs) (95% CIs) of 2.72 (1.77 to 4.20) and 2.12 (1.42 to 3.16) for non-cardia and cardia gastric adenocarcinomas, respectively. Risk of both cancers was also increased when we used other cut points ranging from 3 to 6, or quartile models, or nonlinear continuous models. Risk of OSCC was marginally increased in those with PGI/II ratio <or=4, with HR (95% CI) of 1.56 (0.99 to 2.47), but quartile models and continuous models showed no increased risk. The nonlinear continuous models suggested that any single cut point collapsed subjects with dissimilar gastric adenocarcinoma risks, and that using cut points was not an efficient use of data in evaluating these associations.
CONCLUSION: In this prospective study, we found similar and significantly increased risks of non-cardia and cardia gastric adenocarcinomas in subjects with low PGI/II ratio but little evidence for an association with the risk of OSCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19136509      PMCID: PMC2792746          DOI: 10.1136/gut.2008.168641

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

Review 1.  Pepsinogens, pepsins, and peptic ulcer.

Authors:  I M Samloff; R T Taggart
Journal:  Clin Invest Med       Date:  1987-05       Impact factor: 0.825

2.  Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach.

Authors:  K Kimura
Journal:  Gastroenterology       Date:  1972-10       Impact factor: 22.682

3.  Atrophic chronic gastritis in patients with epidermoid carcinoma of the esophagus.

Authors:  S Rakić; M S Dunjić; P Pesko; M Milićević
Journal:  J Clin Gastroenterol       Date:  1993-07       Impact factor: 3.062

4.  Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia.

Authors:  I M Samloff; K Varis; T Ihamaki; M Siurala; J I Rotter
Journal:  Gastroenterology       Date:  1982-07       Impact factor: 22.682

5.  Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening.

Authors:  M Dinis-Ribeiro; G Yamaki; K Miki; A Costa-Pereira; M Matsukawa; M Kurihara
Journal:  J Med Screen       Date:  2004       Impact factor: 2.136

6.  Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population.

Authors:  W J Blot; J Y Li; P R Taylor; W Guo; S Dawsey; G Q Wang; C S Yang; S F Zheng; M Gail; G Y Li
Journal:  J Natl Cancer Inst       Date:  1993-09-15       Impact factor: 13.506

7.  Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer.

Authors:  W C You; W J Blot; L Zhang; R W Kneller; J Y Li; M L Jin; Y S Chang; X R Zeng; L Zhao; J F Fraumeni
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 Mar-Apr       Impact factor: 4.254

8.  Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer.

Authors:  Hiroshi Ohata; Shintaro Kitauchi; Noriko Yoshimura; Kouichi Mugitani; Masataka Iwane; Hideya Nakamura; Akiyoshi Yoshikawa; Kimihiko Yanaoka; Kenji Arii; Hideyuki Tamai; Yasuhito Shimizu; Tatsuya Takeshita; Osamu Mohara; Masao Ichinose
Journal:  Int J Cancer       Date:  2004-03       Impact factor: 7.396

9.  Serum pepsinogens I and II and stomach cancer.

Authors:  G N Stemmermann; I M Samloff; A M Nomura; L K Heilbrun
Journal:  Clin Chim Acta       Date:  1987-03-16       Impact factor: 3.786

10.  Helicobacter pylori infection, serum pepsinogen level and gastric cancer: a case-control study in Japan.

Authors:  H Fukuda; D Saito; S Hayashi; H Hisai; H Ono; S Yoshida; Y Oguro; T Noda; T Sato; M Katoh
Journal:  Jpn J Cancer Res       Date:  1995-01
View more
  43 in total

1.  Serum pepsinogens and Helicobacter pylori in relation to the risk of esophageal squamous cell carcinoma in the alpha-tocopherol, beta-carotene cancer prevention study.

Authors:  Michael B Cook; Sanford M Dawsey; Lena Diaw; Martin J Blaser; Guillermo I Perez-Perez; Christian C Abnet; Philip R Taylor; Demetrius Albanes; Jarmo Virtamo; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Prediagnostic plasma vitamin C and risk of gastric adenocarcinoma and esophageal squamous cell carcinoma in a Chinese population.

Authors:  Tram Kim Lam; Neal D Freedman; Jin-Hu Fan; You-Lin Qiao; Sanford M Dawsey; Philip R Taylor; Christian C Abnet
Journal:  Am J Clin Nutr       Date:  2013-09-11       Impact factor: 7.045

Review 3.  How to assess the severity of atrophic gastritis.

Authors:  Yan-Cheng Dai; Zhi-Peng Tang; Ya-Li Zhang
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

Review 4.  Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.

Authors:  Parisa Karimi; Farhad Islami; Sharmila Anandasabapathy; Neal D Freedman; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-11       Impact factor: 4.254

5.  Serum pepsinogens in gastric cancer screening.

Authors:  Pelayo Correa
Journal:  Dig Dis Sci       Date:  2010-08       Impact factor: 3.199

6.  The role of serum pepsinogen in the detection of gastric cancer.

Authors:  Nayoung Kim; Hyun Chae Jung
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

7.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

8.  Serum pepsinogen II is a better diagnostic marker in gastric cancer.

Authors:  Xue-Yuan Cao; Zhi-Fang Jia; Mei-Shan Jin; Dong-Hui Cao; Fei Kong; Jian Suo; Jing Jiang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

9.  Evaluation of routine biopsies in endoscopic screening for esophagogastric junction cancer.

Authors:  Xin Niu; Wen-Qiang Wei; Chang-Qing Hao; Guo-Hui Song; Jun Li; Zhao-Lai Hua; Yong-Wei Li; Jun Chang; Xin-Zheng Wang; De-Li Zhao; Guo-Qing Wang; Evelyn Hsieh; You-Lin Qiao
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

10.  Atrophic gastritis: risk factor for esophageal squamous cell carcinoma in a Latin-American population.

Authors:  Emiliano de Carvalho Almodova; Walmar Kerche de Oliveira; Lucas Faria Abrahão Machado; Juliana Rigotto Grejo; Thiago Rabelo da Cunha; Wagner Colaiacovo; Erika Veruska Paiva Ortolan
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.